Holen Sie sich die Stockscreener-App
12.62
0.24%
-0.03
Handel nachbörslich:
12.40
-0.22
-1.74%
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular gets FDA agreement for registrational trial of Axpaxl - MSN
Ocular Therapeutix at H.C. Wainwright: Strategic Moves in Eye Care By Investing.com - Investing.com South Africa
Ocular Therapeutix Inc. Shows Support at Fibonacci LevelMarket Sentiment Review & Consistent Profit Focused Trading Strategies - sundaytimes.kr
Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI - Ophthalmology Times
Ocular Therapeutix™ Receives FDA Agreement Under Special - GlobeNewswire
Ocular Therapeutix's AXPAXLI: A Game-Changer in Diabetic Retinopathy and Wet AMD Markets - AInvest
Ocular Therapeutix Receives FDA Agreement for Axpaxl Trial in NPDR Treatment - AInvest
Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial By Investing.com - Investing.com Australia
Ocular Therapeutix Receives FDA Agreement on AXPAXLI Registrational Trial Design. - AInvest
Ocular Therapeutix Receives FDA Approval for Registrational Trial of AXPAXLI in NPDR, Plans to Outline Clinical Trial Design at Investor Day - AInvest
Revolutionary Once-Yearly Eye Treatment Gets FDA Trial Approval: Could Help 9M Diabetic Retinopathy Patients - Stock Titan
Weaker Q2 Results and Rising Losses Might Change the Case for Investing in Ocular Therapeutix (OCUL) - simplywall.st
Ocular Therapeutix Inc. Stock Poised for Technical ComebackLow Capital High Return Stock Plans Reviewed - beatles.ru
ETF Channel: ITOT Expected to Reach $154 - AInvest
Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report - Yahoo Finance
Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions - TipRanks
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN
RBC Capital Maintains Buy Rating on Ocular Therapeutix with $17 Price Target - AInvest
Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com
Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest
Ocular Therapeutix Reports Second Quarter 2025 Financial Results - VisionMonday.com
Ocular Therapeutix Reports Q2 2025 Financial Results - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix Q2 2025 Sales Down 18%, R&D Expenses Surge 76.9% Amid Reimbursement Pressure - AInvest
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress - TipRanks
OCUL Sales Drop 18% - The Motley Fool
Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations - AInvest
Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data - Investing.com Canada
Ocular Therapeutix Q2 2025 Earnings Call Transcript - MarketBeat
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target By Investing.com - Investing.com South Africa
Clear Street reiterates Buy rating on Ocular Therapeutix stock at $18 - Investing.com Canada
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target - Investing.com India
Earnings call transcript: Ocular Therapeutix misses Q2 2025 earnings, stock drops By Investing.com - Investing.com South Africa
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quant Strategy Flags Ocular Therapeutix Inc. for EntryLow Risk Swing Trade Opportunities Identified - beatles.ru
Ocular Therapeutix tumbles as Q2 results miss estimates By Investing.com - Investing.com South Africa
Ocular Therapeutix tumbles as Q2 results miss estimates - Investing.com India
Ocular Therapeutix: Can AXPAXLI's Pipeline Offset Financial Headwinds? - AInvest
Ocular Therapeutix Q2 Loss Widens, Revenue Falls; Shares Down Pre-Bell - MarketScreener
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (OCUL) Ocular Therapeutix Posts Q2 Net Loss $0.39 a Share, vs. FactSet Est of $0.35 Loss - MarketScreener
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com
Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights - TradingView
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q2 Revenue $13.5M, vs. FactSet Est of $13.6M - MarketScreener
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix raises $97mln, expects cash runway into 2028. - AInvest
What's Next: Ocular Therapeutix's Earnings Preview - 富途牛牛
Ocular Therapeutix stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):